CytoSorbents Corporation is a critical care focused immunotherapy company. The Company utilizes blood purification to modulate inflammation for treating multiple organ failure illnesses and cardiac surgery. The Company's purification technologies are based on biocompatible, porous polymer beads that can remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's product CytoSorb is approved in the European Union as an extracorporeal cytokine filter, designed to reduce the cytokine storm that could cause inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. The Company also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others. In addition, CytoSorb can be used in conditions, such as cardiac surgery, autoimmune disease flares, among others.
|Headquarters||7 Deerpark Dr Ste K|
MONMOUTH JUNCTION, NJ, United States 08852-1921
|Chairman of the Board||Al Kraus|
|President, Chief Executive Officer, Director||Phillip Chan|
|Chief Financial Officer||Kathleen Bloch|
|Chief Operating Officer||Vincent Capponi|
|Chief Medical Officer||Robert Bartlett|
|Shares Out.||25.4M||Book Value||$0.17|
|Annual Dividend Rate||0.00 USD||Price/Sales (TTM)||45.0|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||--|
|Pay Date||1/1/01||Operating Margin||-259.83%|
*GAAP = prior to non-GAAP analyst adjusted earnings.